Skip to main content
Lucid Diagnostics Inc. logo

Lucid Diagnostics Inc. — Investor Relations & Filings

Ticker · LUCD ISIN · US54948X1090 US Human health and social work activities
Filings indexed 250 across all filing types
Latest filing 2025-04-30 Annual Report
Country US United States of America
Listing US LUCD

About Lucid Diagnostics Inc.

https://www.luciddx.com/

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on the prevention of esophageal cancer. The company's primary product is the EsoGuard Esophageal DNA Test, a non-invasive diagnostic tool designed for the early detection of esophageal precancer, including Barrett's esophagus. Utilizing targeted next-generation sequencing (NGS) technology, EsoGuard analyzes DNA biomarkers from cells collected in a simple, office-based procedure. This allows for the screening of at-risk patients, such as those with chronic gastroesophageal reflux disease (GERD), without the need for an initial endoscopy. The company aims to improve patient outcomes by identifying precancerous conditions at a treatable stage, thereby preventing the progression to esophageal adenocarcinoma.

Recent filings

Filing Released Lang Actions
ARS
Annual Report
2025-04-30 English
Proxy Solicitation & Information Statement 2025
Proxy Solicitation & Information Statement
2025-04-30 English
Regulatory Filings 2025
Regulatory Filings
2025-04-25 English
Regulatory Filings 2025
Regulatory Filings
2025-04-18 English
Regulatory Filings 2025
Regulatory Filings
2025-04-11 English
Prospectus 2025
Prospectus
2025-04-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.